Skip to main content
Premium Trial:

Request an Annual Quote

HyperGenomics Signs Contract for Provision of First Revenues

NEW YORK (GenomeWeb News) – HyperGenomics has signed a contract with an undisclosed partner that is expected to provide the firm with its first revenues, its parent firm VolitionRx said today.

The deal calls for Singapore-based VolitionRx to develop epigenetic profiling signatures from blood and makes HyperGenomics eligible for payments of up to a total of US$55,000 if milestones are met during the next eight months.

HyperGenomics is partnering with Biomedicum Genomics in Finland for the sequencing and bioinformatics part of the workflow.

HyperGenomics' technology is based on cutting up a genome at certain spots and then sequencing it. The company's tests are planned for use as a second line upon the diagnosis of cancer, or other disease, in order to determine the specific subtype and decide the most appropriate therapy, it said.

Filed under

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.